Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$77.75 USD

77.75
1,404,313

+1.08 (1.41%)

Updated Jul 10, 2024 01:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is JPMorgan Diversified Return International Equity ETF (JPIN) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JPIN

The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche

by Zacks Equity Research

Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.

AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC

by Zacks Equity Research

The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on data from the phase III FLAURA2 study.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD

by Kinjel Shah

Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.

AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use

by Zacks Equity Research

The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Kinjel Shah headshot

Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN

by Kinjel Shah

FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.

Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection

by Zacks Equity Research

The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.

AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer

by Zacks Equity Research

Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.

FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen

by Zacks Equity Research

The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs

by Kinjel Shah

FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.

AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer

by Zacks Equity Research

The European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast cancer.

Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug

by Zacks Equity Research

Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.

AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study

by Zacks Equity Research

AstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to meet the dual primary endpoints.

Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval

by Zacks Equity Research

Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.

Astrazeneca (AZN) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the most recent trading session, Astrazeneca (AZN) closed at $79.31, indicating a -0.35% shift from the previous trading day.

AstraZeneca's (AZN) Imfinzi Gets FDA Nod in Expanded Use

by Zacks Equity Research

The FDA approves AstraZeneca's (AZN) Imfinzi in combination with chemotherapy for treating mismatch repair deficient advanced/recurrent endometrial cancer based on data from the phase III DUO-E study.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails

by Kinjel Shah

An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.

FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

by Zacks Equity Research

Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Astrazeneca (AZN) Advances But Underperforms Market: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Astrazeneca (AZN) stood at $80.21, denoting a +0.24% change from the preceding trading day.

AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag

by Zacks Equity Research

The FDA grants priority review to AstraZeneca's (AZN) Tagrisso for treating patients with unresectable, stage III EGFR-mutated lung cancer. A decision is due in the fourth quarter of 2024.

GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years

by Zacks Equity Research

GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval

by Kinjel Shah

Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.